Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma

BACKGROUND: Aberrant DNA repair pathways contribute to malignant transformation or disease progression and the acquisition of drug resistance in multiple myeloma (MM); therefore, these pathways could be therapeutically exploited. Ribonucleotide reductase (RNR) is the rate-limiting enzyme for the bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yongsheng, Wang, Yingcong, Xu, Zhijian, Lu, Yumeng, Song, Dongliang, Gao, Lu, Yu, Dandan, Li, Bo, Chen, Gege, Zhang, Hui, Feng, Qilin, Zhang, Yong, Hu, Ke, Huang, Cheng, Peng, Yu, Wu, Xiaosong, Mao, Zhiyong, Shao, Jimin, Zhu, Weiliang, Shi, Jumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097096/
https://www.ncbi.nlm.nih.gov/pubmed/35546402
http://dx.doi.org/10.1186/s12929-022-00813-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097096/
https://www.ncbi.nlm.nih.gov/pubmed/35546402
http://dx.doi.org/10.1186/s12929-022-00813-2

Ejemplares similares